Minerva Neurosciences, Inc. Stock price

Equities

NERV

US6033802058

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 11:43:28 2024-03-28 am EDT 5-day change 1st Jan Change
2.58 USD +3.20% Intraday chart for Minerva Neurosciences, Inc. -1.16% -58.37%
Sales 2024 * - Sales 2025 * - Capitalization 17.48M
Net income 2024 * -32M Net income 2025 * -54M EV / Sales 2024 * -
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * -
P/E ratio 2024 *
-0.7 x
P/E ratio 2025 *
-0.55 x
Employees 9
Yield 2024 *
-
Yield 2025 *
-
Free-Float 77.74%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Minerva Neurosciences, Inc.

1 day-2.72%
1 week-7.41%
Current month-6.37%
1 month-10.71%
3 months-61.54%
6 months-65.75%
Current year-59.35%
More quotes
1 week
2.43
Extreme 2.43
2.75
1 month
2.40
Extreme 2.4
3.03
Current year
2.40
Extreme 2.4
13.49
1 year
1.58
Extreme 1.58
13.49
3 years
1.26
Extreme 1.26
28.28
5 years
1.26
Extreme 1.26
121.72
10 years
1.26
Extreme 1.26
126.72
More quotes
Managers TitleAgeSince
Chief Executive Officer 63 14-02-28
Founder 63 10-06-30
Director of Finance/CFO 58 13-12-31
Members of the board TitleAgeSince
Director/Board Member 66 18-07-16
Director/Board Member 75 14-06-30
Director/Board Member 68 17-12-09
More insiders
Date Price Change Volume
24-03-28 2.56 +2.40% 11 240
24-03-27 2.5 -2.72% 34,730
24-03-26 2.57 -3.38% 37,013
24-03-25 2.66 -0.37% 12,329
24-03-22 2.67 +3.09% 29,335

Delayed Quote Nasdaq, March 27, 2024 at 04:30 pm EDT

More quotes
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company's lead product candidates are roluperidone (MIN-101) and MIN-301. Roluperidone (MIN-101) is a compound that blocks serotonin, sigma, and ? adrenergic receptors that are involved in the regulation of mood, cognition, sleep, and anxiety. The Company is developing roluperidone to treat patients with schizophrenia. Roluperidone is designed to block a specific subtype of serotonin receptor called 5-HT2A. The Company's MIN-301 is a soluble recombinant form of the Neuregulin-1b1 (NRG-1b1), protein, for the treatment of Parkinson's disease and for other neurodegenerative disorders. The Company is also developing seltorexant for the treatment of insomnia disorder and adjunctive treatment of the major depressive disorder (MDD).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
2.5 USD
Average target price
11 USD
Spread / Average Target
+340.00%
Consensus
  1. Stock
  2. Equities
  3. Stock Minerva Neurosciences, Inc. - Nasdaq